Growing together with partners

Please login or
register
21.10.2021
symbolic picture collaboration

Scaling a startup requires support from the entire ecosystem to gain access to customers and users of their solutions. The startups Derma2go, Maptiler, CompPair, Ketl, and Archlet recently won new partners; among them are established companies like Comparis, SAP, and Canon but they are also teaming up with other Swiss start-ups. 

Telemedicine provider derma2go and Switzerland’s largest comparison portal, Comparis, have joined forces to enable derma2go to refer patients to co-operating dermatologists. Patients can inquire about a renowned dermatologist of their choice online in just a few minutes - directly via the Comparis profile of the respective doctors. To benefit from the service, patients must upload pictures of the skin change, answer a questionnaire, and register once. Payment is made via Paypal or credit card. Within 24 hours on weekdays, the attending dermatologist evaluates the findings and creates a therapy plan online. If a medication is required, the patient receives the corresponding prescription or medicines by mail.

Archlet available on SAP Store
The Archlet Sourcing Optimization App
by Archlet is now available on SAP Store, the online marketplace for SAP and partner offerings. The API connector integrates with SAP Aribasolutions and enables advanced sourcing analytics and scenario optimisation capabilities for customers. The App will provide  SAP clients with a range of benefits. These include increasing the sourcing data quality with automated error and outlier detection, reducing tender cycle times by eliminating manual Excel-based analysis, highlighting negotiation opportunities on a supplier level for improved savings delivery, and making holistic sourcing decisions that reflect business constraints and requirements.

KETL wins strategic partnership with Canon
Geneva-based KETL has signed with Canon Inc. a strategic partnership towards innovating document management. Founded in 2019, Ketl uses artificial intelligence (AI) to simplify and structure work based on digital documents, offering solutions that are particularly well suited for the paperless office of law and accounting firms. The integration of Ketl’s technology strengthens Canon’s partner ecosystem and complements Canon’s portfolio of document management solutions to support the automated digitalisation of documents for customers.

MapTiler and Meteomatics
Software mapping provider MapTiler and weather forecast specialist Meteomatics have launched a strategic partnership to bring the former’s weather visualisations on MapTiler’s innovative mapping products. MapTiler now enables its users to integrate Meteomatic’s Weather Data into their applications. On the other hand, Meteomatics’ API users can now visualise weather data on MapTiler and access their WebGL library, enhancing the range of visualisation software available to Meteomatics’ API customers.

CompPair and TWIICE
Lausanne-based CompPair, providing self-healing composites and TWIICE, provider of customer-specific exoskeletons for walking assistance and rehabilitation of people with mobility issues, had a partnership that saw Twiice develop a shoulder rest for its device using healable composites. With its new device, TWIICE won the World Champion title of the Global Innovation Challenge in Japan. With six tasks evaluated, the award recognises organisations that have developed robots that support the autonomous walking of physically challenged individuals.

Biognosys collaborates with Evotec
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients. This partnership will allow the companies to advance the adoption of next-generation proteomics in drug discovery and clinical research. Under the agreement, Evotec will utilise Biognosys’ proprietary proteomics data analysis platform to accelerate and de-risk drug development.

(Press release, RAN)

0Comments

rss